The clinical impact of Prostate Imaging-Reporting and Data System classification in patients with haemospermia undergoing multiparametric magnetic resonance imaging of the prostate

Andrologia. 2021 Jun;53(5):e14041. doi: 10.1111/and.14041. Epub 2021 Mar 10.

Abstract

In this study, we evaluated the role of the Prostate Imaging-Reporting and Data System (PI-RADS) classification of multiparametric magnetic resonance imaging (mpMRI) to determine the likelihood of prostate cancer (PCa) in patients with haemospermia. Fifty-one patients presenting with haemospermia between 2018 and 2020 were included in this retrospective study. Forty-two of the patients (82.4%) were over 40 years, and the median prostate-specific antigen (PSA) level was 1.4 ng/ml. Fourteen of the patients (27.5%) had recurrent haemospermia. All patients underwent mpMRI, and assessments were classified according to PI-RADS v2. The mpMRI revealed PI-RADS one to four lesions in 10 (19.6%), 30 (58.8%), 6 (11.8%) and 5 (9.8%) patients respectively. One patient with PI-RADS 3 and five with PI-RADS 4 lesions underwent cognitive fusion prostate biopsy depending on MRI findings, and two patients with PI-RADS 4 lesions were diagnosed with PCa. Patients with haemospermia and risk factors, that is aged over 40 years, a high PSA level or familial history of PCa, need a more thorough evaluation with mpMRI.

Keywords: classification; haemospermia; multiparametric magnetic resonance imaging; prostate cancer.

MeSH terms

  • Aged
  • Hemospermia* / diagnostic imaging
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Multiparametric Magnetic Resonance Imaging*
  • Prostatic Neoplasms* / complications
  • Prostatic Neoplasms* / diagnostic imaging
  • Retrospective Studies